drugset / Trial / NCT00090194

Improving Transplant Options of Highly Sensitized Recipients Using IGIV-C, 10%

NCT00090194

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine if IGIV-C, 10% will be effective in converting a donor-recipient crossmatch status from positive to negative. The crossmatch test is used to determine if the donor tissue and recipient tissue are compatible. The study will also evaluate if IGIV-C, 10% will allow successful kidney transplantation in a patient who otherwise would not be able to receive a transplant. Three dose levels of IGIV-C, 10% will be evaluated to determine what dose level is most effective.

Timeline

Start
2003-06
Primary completion
Completion
2004-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Immune Globulin Intravenous (Human) Protein / enzyme biologic 0.5 g/kg Intravenous
Subject Immune Globulin Intravenous (Human) Protein / enzyme biologic 1 g/kg Intravenous
Subject Immune Globulin Intravenous (Human) Protein / enzyme biologic 2 g/kg Intravenous